Ken Griffin Scholar Rock Holding Corp Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$7.63 - $9.71 $126,658 - $161,186	16,600 Added 120.29%	30,400 $243,000
Q2 2024 Aug 14, 2024	BUY	$7.84 - $16.79 $29,008 - $62,123	3,700 Added 36.63%	13,800 $114,000
Q1 2024 May 15, 2024	BUY	$13.2 - $17.76 $93,720 - $126,096	7,100 Added 236.67%	10,100 $179,000
Q4 2023 Feb 14, 2024	BUY	$6.52 - $20.32 $652 - $2,032	100 Added 3.45%	3,000 $56,000
Q3 2023 Nov 14, 2023	BUY	$6.02 - $7.76 $17,458 - $22,504	2,900 New	2,900 $20,000
Q1 2023 May 15, 2023	BUY	$7.36 - $12.72 $8,096 - $13,992	1,100 Added 78.57%	2,500 $20,000
Q4 2022 Feb 14, 2023	BUY	$7.02 - $9.76 $9,828 - $13,664	1,400 New	1,400 $12,000

175

75.6M

585K

862K

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $1.97B
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.